Scibase AB Total Liabilities

Latest as of March 2026: Skr45.58 Million SEK ≈ $4.91 Million USD

Scibase AB total liabilities. Based on the latest financial reports, Scibase AB (SCIB) has total liabilities worth Skr45.58 Million SEK (≈ $4.91 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Scibase AB liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Scibase AB (2012–2025)

Total liabilities of Scibase AB from 2012 to 2025. This chart illustrates how Scibase AB's total liabilities have evolved over time, based on quarterly financial data.

Scibase AB Competitors by Total Liabilities

The table below lists competitors of Scibase AB ranked by their total liabilities.

Company Country Total Liabilities
Vigor Kobo Co Ltd
TWO:2733
Taiwan NT$163.17 Million
NSN Co. Ltd
KQ:031860
Korea ₩20.47 Billion
Torrent Capital Ltd
V:TORR
Canada CA$1.42 Million
COINSILIUM GROUP LTD
F:5CT
Germany €161.47K
Optimi Health Corp. Common Shares
NASDAQ:OPTH
USA $5.79 Million
Nukkleus Inc
NASDAQ:NUKK
USA $43.71 Million
Medifron DBT Co. Ltd
KQ:065650
Korea ₩86.61 Billion
Turiya Bhd
KLSE:4359
Malaysia RM35.15 Million

Liability Composition Analysis (2012–2025)

This chart breaks down Scibase AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SCIB total assets.

Liquidity & Leverage Metrics

Scibase AB Total Liabilities Ratios Explained

Scibase AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 4.15 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.78 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.44 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Scibase AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Scibase AB (2012–2025)

The table below shows the annual total liabilities of Scibase AB from 2012 to 2025.

Year Total Liabilities Change
2025-12-31 Skr45.51 Million
≈ $4.90 Million
+81.46%
2024-12-31 Skr25.08 Million
≈ $2.70 Million
+17.87%
2023-12-31 Skr21.28 Million
≈ $2.29 Million
-13.56%
2022-12-31 Skr24.62 Million
≈ $2.65 Million
+67.92%
2021-12-31 Skr14.66 Million
≈ $1.58 Million
+18.31%
2020-12-31 Skr12.39 Million
≈ $1.33 Million
-12.42%
2019-12-31 Skr14.15 Million
≈ $1.52 Million
+46.84%
2018-12-31 Skr9.63 Million
≈ $1.04 Million
-20.95%
2017-12-31 Skr12.19 Million
≈ $1.31 Million
-114.63%
2016-12-31 Skr-83.30 Million
≈ $-8.96 Million
-39.71%
2015-12-31 Skr-138.17 Million
≈ $-14.87 Million
-1641.01%
2014-12-31 Skr8.97 Million
≈ $964.88K
+19.58%
2013-12-31 Skr7.50 Million
≈ $806.90K
-84.23%
2012-12-31 Skr47.56 Million
≈ $5.12 Million
--

About Scibase AB

ST:SCIB Sweden Medical Devices
Market Cap
$12.65 Million
Skr117.59 Million SEK
Market Cap Rank
#26302 Global
#544 in Sweden
Share Price
Skr11.50
Change (1 day)
-5.74%
52-Week Range
Skr0.21 - Skr50.80
All Time High
Skr50.80
About

SciBase Holding AB (publ), a medical technology company, develops and commercializes point-of-care platforms for skin health management in Europe, the United States, North America, Asia, Oceania, and internationally. It operates through Skin Cancer and Skin Barrier Assessment segments. The company offers Nevisense and Nevisense Go point-of-care platforms to detect melanoma and non-melanoma skin c… Read more